Company Profile

Aduro BioTech Inc (AKA: Nanotx Corporation~Oncologic Inc)
Profile last edited on: 8/21/2020      CAGE: 5DG86      UEI: WA5JJNM1Q9Z5

Business Identifier: Engineered Immunotherapy for cancer
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

626 Bancroft Way Suite 3c
Berkeley, CA 94710
   (510) 848-4400
Location: Single
Congr. District: 12
County: Alameda

Public Profile

In June 2020 it was announced that Aduro Biotech would merge with Originally doing business as Nanotx Corpration and then Oncologic, Inc.,in 2008, Triton Biosystems - using heat in treatment of cancer - and Oncologic merged to become Aduro BioTech Inc. The firm is a clinical-stage immunotherapy company with three interconnected and complementary immunotherapy platforms, Listeria, GVAX and Cyclic Dinucleotides (CDNs) with broad applications in oncology, infectious diseases and biodefense. Listeria monocytogenes has been used by immunologists for years as a research tool to study the mammalian immune system, howeve Aduro is engineering Listeria to treat cancer and infectious diseases. Listeria is able to directly targets dendritic cells, one of the most important types of cells in initiating an immune response. After being taken up by dendritic cells, the Listeria delivers the disease antigens into the cytosol, where they are processed by the host cellular machinery and presented to the immune system. It then signals to the innate immune system through multiple pathways, activating cell surface Toll-like receptors and intracellular Nod-like receptors. Unlike other vaccine vectors that can be neutralized by antibodies, Listeria can be repeatedly delivered, is self-replicating and easy to manufacture. GVAX is a portfolio of cell-based immunotherapy vaccines, acquired in 2013 from BioSante Pharmaceuticals Inc, based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine. Aduro believe that the broad antigen expression and the secretion of GM-CSF make GVAX an ideal component of combination immunotherapy. The firm has extensive preclinical and anecdotal human clinical data indicating that the combination of GVAX and Listeria is synergistic and that GVAX is potentiated by the addition of CDNs, potent immune modulators with broad application in both therapeutic and prophylactic vaccines. Cyclic Dinucleotides (CDNs) are small molecules secreted by Listeria and other intracellular pathogens that signal through STING (STimulator of INterferon Genes) to induce a potent immune response.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $224,878
Project Title: Sting-Activating Gm-Csf Secreting Allogeneic Pancreas Tumor Cell Vaccine Therapy
2011 1 NIH $188,315
Project Title: Development Of A Listeria Monocytogenes - Based Therapeutic Hbv Vaccine
2011 2 NIH $271,570
Project Title: Listeria-Based Therapeutic Cancer Vaccine for Melanoma

Key People / Management

  Stephen T Isaacs -- Chairman; President Chief Executive Officer

  Dirk G Brockstedt -- Senior Vice President of Research & Development

  Thomas W Dubensky Jr -- Chief Scientific Officer

  Nancy Kaplan -- Director of Operations

  Peter Lauer -- Director of Molecular Biology

  Seth David Model -- Acting Chief Financial Officer

  Aimee Murphy -- Director of Clinical Operations

  Gregory W Schafer -- Chief Operating Officer

  Justin Skoble -- Director of Technical Operations and Biodefense.